Cyclo Therapeutics has successfully enrolled all participants in the Phase 3 clinical trial of TransportNPC™ for the treatment of Niemann-Pick Disease Type C1. This rare genetic disease is known to be fatal. The trial involves the use of Trappsol® Cyclo™ and results from the 48-week interim analysis are anticipated to be released within the current month. This development marks a significant advancement in the efforts to combat this severe condition.